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Background - Endothelial lipase is a phospholipase with activity against high density 
lipoprotein. Although a small number of mutations in LIPG have been described, the role of 
LIPG in protection against atherosclerosis is unclear.  
Methods and Results - We identified eight loss-of-function (LOF) mutations in LIPG in 
individuals with high HDL-C. Functional analysis confirmed that most rare mutations abolish 
lipase activity in vitro, indicating complete LOF (CLOF), while two more common mutations 
N396S and R476W reduce activity by ~50%, indicating partial LOF (PLOF), and implying 
~50% and ~75% remaining EL function in heterozygous CLOF and PLOF mutation carriers 
respectively. CLOF mutation carriers had significantly higher plasma HDL-C levels compared to 
PLOF mutation carriers. Apo-B depleted serum from CLOF carriers showed significantly 
enhanced cholesterol efflux acceptor capacity, whereas only trends were observed in PLOF 
carriers. Carriers of LIPG mutations exhibited trends toward reduced CAD in four independent 
cohorts (meta-analysis OR=0.7, p=0.04).  
Conclusions - Our data suggest that the impact of LIPG mutations is directly related to their 
effect on EL function, and support that antagonism of EL function improves cardioprotection. 
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Reduction of low density lipoprotein cholesterol (LDL-C) has long been a primary target of 
coronary artery disease (CAD) prevention. However, despite lowering LDL-C with statins, a 
significant residual risk of CAD still remains, emphasizing the need for novel therapies (1). 
Plasma high-density lipoprotein cholesterol (HDL-C) is an independent risk factor and is 
inversely associated with CAD (2). The protective function of HDL-C in CAD is postulated at 
least in part to arise from its role in reverse cholesterol transport, the process whereby excess 
cellular cholesterol is transported to the liver for fecal excretion, and through its anti-
inflammatory, anti-oxidative and anti-apoptotic functions (3).  
Endothelial lipase (EL) is a member of the triglyceride lipase family that includes 
lipoprotein lipase (LPL) and hepatic lipase (HL). LPL primarily acts on TG-rich ApoB 
containing lipoproteins, HL acts on all classes of lipoproteins and EL acts preferentially on HDL 
lipids (4).  
 Studies of EL functionality in mice by overexpression and gene targeting show altered 
plasma HDL-C levels by affecting the fractional catabolic rate of HDL (5). One model suggests 
that EL hydrolyzes HDL phospholipids, generating smaller PL-depleted HDL particles that are 
more rapidly catabolized (6). Studies in humans also suggest that mutations that reduce EL 
activity correlate with increased plasma HDL-C levels (7, 8). 
 The role of EL in modulating risk for CAD is unclear. Male Lipg-/- mice show increased 
plasma HDL-C, phospholipid and LDL-C (9, 10) as well as increased HDL particle size (9). 
Associated with this, aortic lesions are reduced in Lipg-/- x ApoE-/- mice (9). However, aortic 
lesions are not changed in another model of Lipg-/- x ApoE-/- or in Lipg-/- x Ldlr-/- (10), and the 
reasons for this discrepancy are not readily apparent.  
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It is unclear in humans whether loss of function of LIPG leading to raised HDL-C levels 
confers a decreased risk for atherosclerosis. 
Here we have assessed the effects of CLOF and PLOF LIPG mutations on HDL-C levels, 
HDL functionality and risk for CAD. Individuals with heterozygous mutations in LIPG show 
significantly increased plasma HDL-C and improved HDL functionality. In addition, mutations 
in LIPG are associated with reduced atherosclerosis. 
Results
Mutations in LIPG have discrete and diverse effects on EL function
We sequenced a cohort of 177 unrelated individuals with extreme high HDL-C (HDL-????th
percentile), in whom mutations in CETP, GALNT2, LCAT, LPL, APOAI and ABCA1 had been 
excluded, and identified 23 individuals with 8 different LIPG mutations, six of which are novel 
(Table 1) (Fig 1A). To determine if these mutations impact EL function, we utilized a fluorescent 
phospholipid substrate to quantify EL activity (11). All mutants showed significantly lower 
phospholipase activity compared with wt EL (Fig 1B). The LIPG mutations E391K, N396S and 
R476W showed partial loss of function (~50%). All the other mutations showed EL activity that 
was significantly different from wild-type and not different from mock transfected supernatants 
(CLOF) (Fig 1B). The 5? UTR mutation M1-18T>C was not generated in vitro because a cDNA 
construct with a CMV promoter was used. Thus, in vitro data suggests that the catalytic domain 
of EL (amino acids 169-274) does not tolerate missense sequence changes. However, missense 
mutations in the c-terminal lipase domain of EL (amino acids 347-482) still retain partial activity 
in vitro. Thus, mutations in LIPG have variable impact on EL function.  
Plasma HDL-C is highest in CLOF mutation carriers
Extrapolation of the observed in vitro effects of LIPG mutations to EL activity in vivo suggests  
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that heterozygous PLOF carriers will retain at least 75% of EL activity, whereas heterozygous 
CLOF carriers will retain at least 50% of EL activity. We extended the pedigrees of the probands 
to identify additional carriers of mutations in LIPG (Table 2), and assessed plasma HDL-C levels 
in mutation carriers (n=131) compared to unrelated population controls (n=756).  
Carriers of LIPG mutations showed a significant 15.5mg/dL (28.7%) increase in HDL-C
compared to unrelated controls (p=0.005; Table 3). Carriers of CLOF mutations showed a 23.2 
mg/dL (42.9%) increase in plasma HDL-C, whereas carriers of PLOF mutations only showed a 
13mg/dL (24.5%) increase (Table 4). No significant changes in plasma LDL-C, triglycerides or 
BMI were observed in carriers compared to controls (Table 3). No differences were observed in 
alcohol consumption, smoking, and history of diabetes or hypertension (data not shown). 
Thus, the in vitro effects of various LIPG mutations correlated with the in vivo effects as 
measured by HDL-C levels. In our cohort, one individual was a compound heterozygote, 
carrying H220Q, a CLOF mutation, and N396S, a PLOF mutation. This individual would be 
expected to have only 25% of remaining EL activity. Consistent with this high level of EL 
inhibition, this individual showed a 54.6mg/dL (100.9%) increase in plasma HDL-C compared to 
controls (Table 4). In addition, 2 individuals were homozygotes for the PLOF mutation N396S 
(Table 4, Fig 1C).  
Carriers of PLOF mutations show marked variability in HDL-C levels 
We next assessed the variability of HDL-C levels in partial and complete LOF carriers. We 
defined high expressivity as those with HDL-????th percentile after adjusting for age and sex, by 
comparing the HDL-C level of each carrier to those of age and sex matched individuals in the 
Lipid Research Clinic (LRC) database. A total of 83.4% of individuals with CLOF mutations had 
HDL-C levels greater than the 80th percentile, compared to only 69.6% of persons with the PLOF 
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mutation R476W and 62% of persons with the PLOF mutation N396S (N396S vs CLOF: 
p=0.03; R476W vs CLOF: p=ns; Fisher’s exact test) (Fig 1D). These data indicate that N396S 
and R476W represent relatively mild mutations that show variable effects on HDL-C levels in 
humans. 
Increased cholesterol efflux acceptor capacity in LIPG mutation carriers  
HDL-C levels are correlated with susceptibility to atherosclerosis (2), but measures of HDL 
functionality show similar or even stronger correlation with CAD (12, 13). In addition, HDL 
functionality has effects on CAD independent of HDL-C levels (12). One aspect of HDL 
functionality, lipid efflux, may be a stronger predictor of CAD than HDL-C levels, and it was 
recently noted that every 1 standard deviation increase in lipid efflux was correlated with a
significant ~25% decrease in CAD in humans (13).  
Efflux of cholesterol from macrophages to ApoB-depleted serum from CLOF mutation 
carriers was significantly increased (% efflux: controls: 16.3±1.5 (n=4); CLOF: 19.6±2.4 (n=5), 
p=0.04) (Fig2A). This was less apparent in PLOF mutation carriers where efflux acceptor 
capacity was elevated but not significantly different from controls (PLOF: 17.7±2.5 (n=9), 
p=0.3) (Fig 2A).  
The impact of anti-inflammatory and anti-oxidative effects of HDL on CAD has also 
recently been described (14). We determined if HDL from LIPG mutation carriers displayed 
these properties, by quantifying VCAM-1 expression and superoxide production. We found no 
significant differences in either of these parameters. However, a trend toward decreased (by 
53%) superoxide production was observed in mutation carriers (Supplementary figure 1). 
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LIPG mutation carriers have larger HDL particles and increased large HDL particle 
concentration
We next performed NMR analyses on HDL from LIPG mutation carriers. HDL from CLOF 
carriers was larger in size (CLOF: 10.2±0.6 nm, n=4; controls: 9.2±0.6 nm, n=6, p=0.04) (Fig 
2B). No changes in LDL or VLDL particle sizes were observed (data not shown). The increase in 
HDL size was less apparent in PLOF carriers, and was not significantly different from controls 
(PLOF: 9.6±0.6, n=9, p=0.3). The concentration of large HDL particles was also significantly 
increased in CLOF carriers compared to both PLOF carriers and controls (CLOF: 12.6±3.2, n=6; 
controls: 5.1±2.9 μmol/L, n=4, p=0.006; PLOF: 8.6±3.5, n=9, p=0.04) (Fig 2C). No changes in 
concentration of VLDL and LDL particles were observed. The concentration of large particles in 
PLOF carriers was not significantly different from controls (p=0.1). Increased HDL particle size 
and increased large HDL particle concentration have been associated with reduced CAD (15,
16). HDL particles were also assayed using 2-D gel electrophoresis. A specific ~50% increase in 
?-1 HDL was observed in the CLOF carriers (CLOF: 21.7±4.8, n=4; controls: 14.5±3.8, n=5, 
p=0.047, Fig 2D), whereas no change was observed between PLOF carriers and controls 
(PLOF= 20.3±7.6, n=9, p=0.2).  
HDL from LIPG mutation carriers is enriched in phospholipids
The efficiency of lipid efflux acceptors depends on HDL phospholipid content (17, 18). We 
assessed the lipid composition of HDL isolated from LIPG mutation carriers. EL has high 
phospholipase activity toward HDL (4, 6). In agreement with this, HDL from carriers was 
enriched in phosphatidylcholine (PC) (controls: 541.2±187.7, n=4; CLOF: 695.4±132.2, n=6, 
mg/mL, p=0.16, Fig 2E). This data suggests that increased HDL phospholipid content in carriers 
result in improved efflux capacity.  When PC subspecies were quantified, longer chain length 
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PCs (38-carbon) were significantly increased in HDL from CLOF compared to controls (CLOF= 
156.6±37.8 mg/ml, n=6; controls= 96.1±39.2, n=4, p=0.04, Fig 2F). No significant difference 
was observed between PLOF carriers and controls. A trend to increased 36-carbon PCs was also 
observed in CLOF compared to PLOF carriers and controls. No differences in 34-carbon length 
PCs were observed irrespective of mutation strength (Fig 2F). These data suggest that EL acts 
preferentially on long chain PCs. 
Assessment of atherosclerosis in LIPG mutation carriers
We assessed the impact of LIPG mutations on risk for CAD in the 131 family based mutation 
carriers compared to unrelated controls. A non-significant trend toward decreased CAD in 
mutation carriers was seen (carriers: 14/131 (10.7%) with CAD; unrelated controls: 111/756 
(14.7%) with CAD, OR=0.69; 95%CI=0.39:1.25; p=0.28) (Table 5). Power calculations show 
we had 80% power to observe a significant association with CAD for an effect size of OR=0.37 
or less, due to the low number of mutation carriers in this cohort.  CLOF mutation carriers had 
lower CAD than either PLOF carriers or controls (CLOF: 2/22 (9.5%) with CAD; PLOF: 11/107 
(13.2%) with CAD; controls: 111/756 (14.7%) with CAD, p=ns for all comparisons). In addition, 
the age at onset of CAD was significantly delayed in carriers of CLOF mutations compared to 
controls (CLOF: 72.0±4.2 yrs; PLOF: 64.6±12.7; controls: 51.1±11.7; CLOF vs controls:
p=0.01; CLOF vs PLOF: p=ns). 
To further extend these findings, we assessed CAD rates in mutation carriers in the 
Rotterdam cohort, a prospective, population based cohort (19). Although N396S and R476W are 
PLOF mutations, they are the most frequent mutations in Caucasians (Population frequency: 
N396S ~2.2%, R476W ~1%). Thus, these two mutations were genotyped in the Rotterdam 
cohort. As in the family based cohort, a non-significant decrease in CAD was observed in 
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mutation carriers (carriers: 17/156 (10.9%) with CAD; controls: 752/5658 (13.3%) with CAD, 
p=0.37, OR=0.79, 95%CI=0.48-1.32) (Table 5). CAD was defined as fatal or non-fatal 
myocardial infarct. The missing data rate was ~4% for this cohort. 
We next selected two cohorts with high risk for CAD and therefore with greater power to 
assess the impact of LIPG mutations on CAD in populations of small size. Again, N396S and 
R476W, the two most frequent mutations were assessed, even though they showed only small 
effects on EL function. We first utilized the GiraFH cohort, a retrospective, multi-center cohort 
of 2068 individuals with familial hypercholesterolemia (FH) (20). In contrast to the family and 
Rotterdam cohorts in which the CAD rate was ~14%, the CAD rate in the GiraFH cohort was 
~30% with an average age of onset of 48.8±10.9yrs. A trend towards reduced CAD that did not 
reach statistical significance was observed in mutation carriers (carriers: 11/57 (19.3%) with 
CAD; controls: 579/2011 (28.8%) with CAD, p=0.12, OR=0.59, 95%CI=0.31-1.15) (Table 5).  
We next assessed the frequency of LIPG mutations in the PAS cohort, a cohort with 
premature atherosclerosis where cases were recruited as part of a prospective cohort with 
symptomatic CAD before the age of 51 years, defined as MI, coronary revascularization, or 
evidence of at least 70% stenosis in a major epicardial artery (21). DNA samples from blood 
donors at routine Sanquin Blood Bank donations were controls. If mutations in LIPG are 
associated with reduced CAD, then we expect lower mutation frequency in those with premature 
CAD. Indeed, the frequency of LIPG mutations in the PAS cohort was 2.1%, whereas the 
frequency of mutations in controls was 3.2% (p=0.2, OR=0.66, 95%CI=0.36-1.28) (Table 5). 
Combined meta-analysis of the Rotterdam, GiraFH and PAS cohorts showed an OR of 
0.7 with p=0.037 (95%CI=0.50-0.98) (Table 6). Thus, when cohorts were pooled, a reduction in 
CAD in LIPG mutation carriers is observed. However, underestimation of the impact of LIPG
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mutations on atherosclerosis may have occurred since only the two PLOF LIPG mutations with 
small effects on HDL were assessed in three of the four cohorts.  
Discussion
In this study, we have identified six novel and two previously described mutations in LIPG
through sequencing of a cohort of high HDL-C individuals. We show that mutations in LIPG
result in significantly increased plasma HDL-C and changes in HDL function compatible with 
cardioprotection. The effect of these mutations on HDL-C levels and HDL functionality is 
directly correlated with the impact of these mutations on EL activity. In addition, our data 
indicate that mutations in LIPG may confer protection against atherosclerosis.  
Measures of HDL functionality show similar or even stronger correlation with CAD 
compared to that between HDL-C and CAD (12, 13). ApoB-depleted serum from individuals 
with CAD displays significantly reduced efflux acceptor capacity, confirming in humans that 
efflux capacity is robustly and inversely correlated with atherosclerosis (13). Using identical 
methodology, we found that ApoB-depleted serum from CLOF mutation carriers displayed 
significantly improved macrophage cholesterol efflux capacity. The phosphotidylcholine content 
of HDL particles is critical for efficiency of cholesterol efflux acceptors (17, 18). HDL isolated 
from CLOF mutation carriers showed increased phosphotidylcholine content, agreeing with the 
fact that EL is a phospholipase, and providing the mechanism underlying the improved efflux 
capacity. PLOF carriers showed trends towards improved efflux capacity. We assessed the 
impact of HDL on anti-oxidative and anti-inflammatory endothelial function (14), and found no 
significant effect of LIPG on these parameters. A non-significant 53% reduction in superoxide 
production was observed in mutation carriers, suggesting a beneficial effect of this HDL on anti-
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oxidative capacity. Overall, no significant adverse effects of LIPG reduction on HDL 
functionality were observed. 
We next assessed the impact of LIPG mutations on CAD in humans. An important caveat 
is that many carriers of the two PLOF LIPG mutations, N396S and R476W, do not display 
elevated plasma HDL-C levels. Thus, if EL has an impact on atherosclerosis, and this is 
mediated through raised HDL-C, then utilizing only these mutations to assess the impact of EL 
on atherosclerosis will significantly undermine the effect. Despite this caveat, since these two 
mutations are by far the most frequent, we used them to assess the impact of LIPG on 
atherosclerosis.
Studies assessing the impact of genes modulating plasma HDL-C levels on 
atherosclerosis have been equivocal. One major factor contributing to this is the study of mild 
mutations with small effects on HDL-C levels as a surrogate for CLOF mutations. Selection of a 
few mutations with modest effects on protein function as a proxy for the inhibition of the 
majority of protein function often results in variable findings. However, in general, the more 
frequent mutations in populations tend to be mild LOF mutations, requiring the study of these in 
order to achieve adequate power.  
Another factor significantly confounding such studies is the low risk for CAD in the 
general population. In addition, the baseline HDL-C levels from which elevation occurs 
significantly influence the impact of HDL-C on atherosclerosis. Increasing HDL-C from a 
baseline of 45mg/dL or greater does not provide much additional benefit against CAD (22, 23). 
Other lipoproteins such as LDL are also important, with greater impact on CAD being observed 
when HDL-C is increased in the presence of high LDL-C (22). These factors led us to select for 
further assessment, two cohorts with high atherosclerosis incidence, one with individuals with 
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familial hypercholesterolemia (GiraFH), and the other with individuals with premature 
atherosclerosis (PAS). An alternate strategy was to perform association studies in a very large 
unselected population cohort. However, because of the mild dysfunction of the two most 
common LIPG mutations, and the low rate of CAD in unselected populations, we chose to study
selected cohorts.
We found that mutations in LIPG result in a trend toward protection against CAD in four 
different cohorts. When a combined meta analysis was performed, we observed a significant 
~30% reduction in CAD in LIPG mutation carriers
The role of LIPG activity in atherosclerosis is unclear. Plasma EL concentrations are 
significantly increased in a cohort with metabolic syndrome and subclinical CHD (24), as well as 
in cultured endothelial cells in response to pro-inflammatory cytokines, and in humans during 
acute inflammation (25), suggesting a correlation between EL levels and the development of 
atherosclerosis. However, EL enhances the selective uptake of HDL-C though a SR-B1 mediated 
pathway (26), suggesting an atheroprotective role. In contrast, overexpression of EL resulted in a 
significant decrease in macrophage to feces reverse cholesterol transport (RCT) (27), although 
RCT was unchanged in Lipg-/- mice (28). Several human studies have assessed the impact of 
variants in LIPG on atherosclerosis. However, the majority of these studies assessed the variant 
584C/T (T111I), which has no functional effect on LIPG (8) and thus is unlikely to modulate 
CAD risk. Two studies showed significantly reduced atherosclerosis in carriers of the T111I 
variant (29, 30), both independent of plasma HDL-C. However, since this variant does not 
influence EL activity directly (8), it is possible that the association with CAD resulted from this 
variant being in linkage disequilibrium with other loss of function LIPG mutations in these 
populations. A third study showed no impact of this variant on risk of CHD or on plasma HDL-C
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levels (31) and a fourth showed no association between this variant and CAD, although carriers 
of the variant showed increased plasma HDL-C (32). The intronic variants C+42T/In5 and 
T+2864C/In8 were associated with fewer myocardial infarctions, although significance was lost 
after multiple testing (33). Two other SNPs in the 3'UTR of LIPG also showed no altered risk for 
CAD (34, 35). However, if these SNPs affect EL function is unknown.  
Two studies thus far have assessed the association between a LIPG mutation known to 
compromise LIPG function and atherosclerosis. The first study assessed the association between 
the partial LOF N396S mutation and a surrogate marker for CAD, intima media thickness (IMT), 
and found no association, although plasma HDL-C levels were mildly increased (8). However, 
this study was performed in only four N396S mutation carriers and no conclusions can be 
reached from such a small study. The next study also assessed the impact of the mild N396S 
mutation on MI (36). Although >100,000 individuals from 20 different cohorts were assessed, 
overall, no impact of N396S on MI risk was observed (36). Numerous factors may have 
confounded this analysis. One crucial issue is HDL-C levels in the controls, and not just the 
magnitude of increase in carriers. The impact of HDL-C on cardiovascular risk is not linear and 
is curtailed in people with higher HDL-C levels (22, 23). Smaller increases from lower HDL 
levels confer larger impact on CAD risk compared to similar increases from higher baseline 
HDL (>45mg/dL) (22, 23). Another factor may be that the HDL-C increase was too small to 
detect an impact on MI. The authors used an HDL-C increase of 0.14mmol/L to predict the 
impact on MI, and for power calculations. However, of the 6 prospective cohorts, 3 had HDL-C
increases of only 0.03, 0.04 and 0.08 mmol/L (the other 3 cohorts each had an increase of 
0.14mmol/L), thereby perhaps resulting in an underpowered study. Another factor is that HDL-C
levels are only reported for the 6 prospective cohorts. Thus, if HDL-C was increased in the 14 
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case-control cohorts is unknown. Yet another factor may be the variety of ethnicities and 
environments represented by the 20 cohorts, and may explain the vastly varying impacts on MI 
for each cohort.  
Recently, it was demonstrated that the mass and activity of EL isolated from individuals 
with cardiovascular disease was significantly higher than those without CAD (37), suggesting a 
direct correlation between EL activity and atherosclerosis. In addition, plasma EL activity was 
significantly correlated with coronary risk scores in the Framingham Study (37).
 Our current study using human mutations does not model the almost complete inhibition 
of EL achievable with drugs. However, the major impact of homozygous and compound 
heterozygous mutations on plasma HDL-C, along with the increasing efflux functionality 
observed with decreasing EL activity suggests that inhibition of EL could be cardioprotective. 
Materials and Methods:
Patients
Subjects were selected from the Lipid Clinic Network and Vascular Research Network 
(Amsterdam, Netherlands) and through the Centre for Molecular Medicine and Therapeutics 
(Vancouver, Canada). The main criterion was HDL-????th percentile, adjusted for age and 
gender, in unrelated probands. Families of unrelated probands were expanded, and detailed 
pedigrees generated. All individuals of families in which the high HDL proband had a mutation 
in LIPG were genotyped to assess segregation of the high HDL-C trait with LIPG mutations. All 
carriers of LIPG mutations were pooled, and compared to pooled non-carrier controls consisting 
of first-degree relatives of each mutation carrier. The Ethics Committees of the Academic 
Medical Center, Amsterdam and the University of British Columbia, Vancouver accepted the 
protocol for genetic analysis. All subjects signed informed consent forms. 
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 Fasting blood was drawn into EDTA-containing tubes and plasma and stored at -80°C. 
Leukocytes were isolated for DNA extraction. Lipoprotein measurements were performed as 
described (38). 
DNA sequencing
DNA primers were designed to flank LIPG exons and adjacent intron boundaries as defined in 
the UCSC (hg18) release of the human genome (http://genome.ucsc.edu/). Reference 
DNA/Protein sequences used for sequencing and data analysis include NM_006033.2 and 
NP_006024. Primer sequences were designed using Primer3 (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). PCR products were amplified, purified using the AMPure kit 
(Agencourt, Beverly, MA), and sequenced by fluorescent dye-terminator chemistry (Seqwright, 
Houston TX). Known and novel SNPs in each gene were identified from sequence analysis using 
Sequencher v 4.9 (Ann Arbor, MI) and confirmed in dbSNP build 130 (NCBI,
http://www.ncbi.nlm.nih.gov).   
In vitro functional assessment of LIPG mutations
All identified mutations were designated novel based on published literature and if absent from
dbSNP (Build 130). Functional impacts were predicted using Polyphen 2.0 
(http://genetics.bwh.harvard.edu/pph2/). All mutations except the promoter splice site Met1-
18T>C mutation were generated in a LIPG cDNA clone (Origene) by site directed mutagenesis 
(Stratagene). Sense primers: Leu130Phe, cccaccagtttacacggatgcggtcaataatacc; Gly196Arg, 
ggtttggatcctgccaggcccatgtttgaagg; His220Gln, gcagattttgtggatgtcctccagacctacacg, Glu388Stop, 
ggaaatagtgtagcggatcgagcagaatgc; Glu391Lys, ggaaatagtggagcggatcaagcagaatgc; Asn396Ser, 
gcagaatgccaccagcaccttcctggtctacacc; Arg476Trp, gcatatccccaggctgggagctctggtttcg. Anti-sense 
primers were complementary to the sense primers. Positive clones were sequence confirmed. EL 
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protein was generated by Lipofectamine (Invitrogen) mediated transient transfection into 
HEK293T cells. 72 hours post-transfection, cells were incubated with 750U of heparin for 30 
minutes at 37°C and media was concentrated, followed by centrifugation at 1500g for 30 minutes 
(4°C). Cleared supernatant was stored at -80°C. Cells in PBS were centrifuged at 800g for 5 
minutes (4°C) and lysed in 100ul lysis buffer (0.025M ammonium chloride pH, 5mM EDTA, 
0.4mg/mL SDS, 8.0mg/mL Triton-X 100 with proteinase inhibitor and heparin). Following 
sonication and centrifugation, supernatants were stored at -80°C. Proteins resolved on NuPage 
12% BisTris gels (Invitrogen) were transferred to PVDF membranes and probed with antibodies 
to the N-terminus of EL (Abcam: ab14797). Bands were visualized with Supersignal 
Chemiluminescent Substrate (Thermo) on X-Ray Film (Thermo). Analyses of the lipase activity 
were performed using a fluorescent phospholipid substrate as described (11). A kinetic read was 
carried out for each sample, and a time-point was chosen in the linear range of the assay to 
ensure that the reduced activity of LIPG mutants did not arise from insufficient substrate. 
HDL functionality assessments 
Fasting plasma and serum was collected from LIPG mutation carriers and snap frozen. For lipid 
efflux studies, frozen sera were analyzed by Vascular Strategies LLC, using established 
protocols (13, 39). This assay quantifies total cholesterol efflux mediated by pathways of known 
relevance in macrophages (ABCA1 and G1, SR-BI, and aqueous diffusion). Briefly, J774 murine 
macrophages were labeled with 2μCi/mL 3H cholesterol for 24 hours in the presence of ACAT 
inhibitor (Sandoz 58-035) and equilibrated overnight with 0.3 mM 8-(4-chlorophenylthio)-cyclic 
AMP in the presence of ACAT inhibitor. ApoB-depleted serum was obtained by PEG 
precipitation. 2.8% v/v ApoB-depleted serum was used as efflux acceptor for 4 hours. 20 μg/ml 
apoA-I, 20 μg/ml HDL3, 2% v/v human serum and medium alone were used as controls. Efflux 
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was quantified by liquid scintillatio . For lipoprotein particle sizes and concentrations, proton 
NMR spectra of each plasma specimen (0.2 mL) were acquired in replicates using an automated 
400-MHz lipoprotein analyzer at LipoScience (Raleigh, NC) following described protocols (40). 
For HDL subfraction analysis, 2-D gel electrophoretic separation was performed by Dr. Bela 
Asztalos using established protocols (41). HDL composition analysis was carried out by isolating 
the HDL particles using gradient gel electrophoresis (GGE) (Lipoprint TM, Quantimetrix, CA). In 
brief, 25 μl of plasma was loaded onto the gel following manufacturer’s instructions. The gels 
were stained with Sudan Black to locate lipoprotein bands for excision. Excised lipoproteins 
were utilizing the Bligh and Dyer method (42) and analyzed by high-resolution liquid 
chromatography/mass spectrometry (LC/MS) (Synapt G2 HDMS, Waters Corp., Manchester, 
UK) as previously described (43). For the anti-oxidative and anti-inflammatory functions of 
HDL, superoxide production and VCAM-1 expression were respectively quantified as previously 
described (14).
Genotyping of cohorts 
The Rotterdam, GiraFH and PAS cohorts were genotyped using taqman probes (ABI) following 
manufacturer’s instructions (ABI).  
Statistical Analyses 
Regression modeling was used to test for association between lipid measurements and the 
genetic carrier status versus non-carrier status. Proc Glimmix in SAS software version 9.3 was 
used with a random effect variable to account for the families from which carriers were 
ascertained. Adjustment for age and sex was used for test of lipid parameters except for HDL 
percentiles, which already take into account age and sex. We assumed a dominant model, 
combining the heterozygous and homozygous carriers of the mutations. Fisher exact tests were 
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used for proportional comparisons. For meta-analyses, a fixed effects model was used and no 
adjustments for multiple testing of SNPs within each study were used or for familiarity of 
samples in those tests. Fisher's Z-score was used to capture each study's effect and to generate a 
summary correlation statistic. Analyses were conducted using Comprehensive Meta Analysis 
version 2.2.050.  
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Table 1: LIPG mutations identified, their conservation and predicted functional effect 
Mutation   Novel      Vertebrate Conservation    Predicted Effect
Met1-18 T>C     Yes            Conserved to lizard           Protein translation reduced 
L130F                  Yes         Conserved to stickleback             Probably damaging 
G196R                 Yes         Conserved to stickleback             Probably damaging 
H220Q                Yes          Conserved to stickleback             Probably damaging 
E388X                 Yes          Conserved to stickleback             Probably damaging 
E391K                 Yes                  Gln tolerated                        Possibly damaging 
N396S                 No           Conserved to stickleback              Possibly damaging 
R476W                No           Arg, Lys, Gln tolerated                Possibly damaging 
Table 2: Number of LIPG mutation carriers by mutation
Mutation     Number of mutation carriers 
 N396S    81 
R476W   27 
L130F    12 
H220Q    4 
G196R     3 
E388X     2 
E391K     1 
Met1-18G>T   1 
One individual has a H220Q and a N396S mutation 
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Table 3: Plasma lipid levels in LIPG mutation carriers 
Carriers Unrelated 1st degree p-value 1 p-value1 
Controls        relative controls        carriers vs                carriers vs
                  unrelated controls  1st degree relatives
N  131  756  123  
% male             71/131 (54.2%)   367/756 (48.5%) 53/123 (43.1%)           0.97                          0.09
Age (yrs)               43.8 (19.7)         53.2 (13.5)         39.8 (18.8) 0.011                        0.13 
HDL-C (mmol/L)  1.80 (0.71)         1.40 (0.60)          1.54 (0.52)              0.00481                     0.00003
HDL%ile  72.7 (30.5)         48.8 (34.9)          59.2 (30.6)              0.00936                    0.00028
LDL-C (mmol/L)   3.26 (1.09)         3.30 (0.97)          3.10 (1.14)             0.4473                      0.83075
TC (mmol/L)        5.60 (1.33)         5.32 (1.16)          5.14 (1.28)              0.06301                    0.02057
TG (mmol/L)        1.17 (0.72)         1.36 (0.98)          1.07 (0.67)               0.54617                     0.63620
BMI (kg/m2)           23.8 (3.9)           25.7 (4.0)           23.1 (5.1)               0.32677                     0.93010
1General linear mixed model with a random variable to account for family membership and adjustment for age and 
sex when appropriate. Values are: average (standard deviation).
Table 4: HDL-C elevation in partial and complete loss of function LIPG mutation carriers
                            N                           HDL-C                        HDL-C increase                % HDL 
Unrelated controls                    756  54.1(23.2)
N396S                        80  68.1(28.2)  14.0  25.9%
R476W                        27  66.9(28.2)  12.8  23.7%
Complete LOF                       23  77.3(21.5)  23.2  42.9%
Compound heterozygote 1            108.7  54.6   100.9%
N396S homozygotes                  2  94.7(2.7)  40.6  75.0%  
p-value (N396S vs controls)  5.50E-07
p-value (R476W vs controls)            0.005
p-value (CLOF vs controls)  3.6E-06
p-value (N396S homozygotes vs controls)                 0.3
HDL-C and HDL-C increase are in mg/dL. Values are average (standard deviation).
Copyright by American Heart Association, Inc. All rights reserved.
DOI: 10.1161/CIRCGENETICS.111.962613
24
Table 5: LIPG mutation carriers with atherosclerosis 
                            N  LIPG carriers with CAD                 Controls with CAD                 p-value
Family cohort (total)       887                 14/131 (10.7%)                            111/756 (14.7%)                    0.28
Family cohort (PLOF)        12/108 (11.1%)                 111/756 (14.7%) 0.38
Family cohort (CLOF)       2/23 (8.7%)    111/756 (14.7%)  0.56
Rotterdam                      5814                 17/156 (10.9%)                          752/5658 (13.3%)                     0.37
GiraFH                           2068                 11/57 (19.3%)                            579/2011 (28.8%)                     0.12
                N          LIPG carriers in CAD cohort      LIPG carriers in control cohort      p-value
PAS/Sanquin             665/1078 14/665 (2.10%)   34/1078 (3.15%)                      0.24
Controls = Non-LIPG mutation carriers. Values are average (standard deviation). 
Table 6: Meta analysis of LIPG mutation carriers with atherosclerosis
Cohort     Carriers    Carriers   Controls    Controls   OR    Lower    Upper    Fisher’s   p-value 
with        without       with        without               limit       limit          Z
      CAD CAD CAD         CAD
Rotterdam   17             139          752          4875      0.79      0.48       1.32       -0.89        0.37 
GiraFH        11              46       579          1432      0.59      0.30       1.15       -1.55        0.12 
PAS          14   34      651          1046      0.66      0.35   1.24     -1.29        0.20 
Fixed Effect               0.696    0.496     0.979      -2.083 0.037
Figure Legends:
Figure 1: Functional characterization of LIPG mutations. (A) A schematic of the EL protein 
with the locations of the mutations indicated. Mutations were found throughout the EL protein. 
(B) Quantification of EL activity in transfected cell culture supernatants using a fluorescent 
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phospholipid lipase assay (n=3, each n in duplicates). All LIPG mutations showed decreased EL 
activity compared to wt, with mutations in the lipase domain displaying only ~50% inhibition of 
EL function, whereas all other LIPG mutations showed complete loss of EL activity. (C) Plasma 
HDL cholesterol levels in control (WT, n=756), heterozygous and homozygous partial loss of 
function, heterozygous complete loss of function, and a compound heterozygous individual are 
graphed against the projected inhibition of EL in the mutation carriers, based on the in vitro
activity of the mutations. (D) The number of individuals with HDL-C<80th percentile was 
increased in the partial LOF mutation carriers (N396S and R476W) compared with carriers of 
the complete LOF mutations.
Figure 2: Functionality of HDL from LOF LIPG mutation carriers. (A) ApoB-depleted 
serum from complete LOF mutation carriers showed a significantly increased macrophage 
cholesterol efflux acceptor capacity, whereas partial LOF carriers were no different from 
controls. Wt: n=4; PLOF: n=9; CLOF: n=5. (B) NMR analysis showed a significant increase in 
HDL particle size in complete and not partial LOF LIPG mutation carriers. Wt: n=4; PLOF: n=9; 
CLOF: n=6) (C) NMR analysis also showed a significant increase in the concentration of large 
HDL particles in complete and not partial LOF mutation carriers Wt: n=4; PLOF: n=9; CLOF: 
n=6) (D) By 2-????????????????????????????????????????????????????????-1 HDL particles was 
observe in complete LOF mutation carriers. Wt: n=5; PLOF: n=9; CLOF: n=4. (E) The 
concentration of phosphatidylcholine was increased in HDL isolated from LIPG mutation 
carriers, but did not reach significance. Wt: n=4; PLOF: n=8; CLOF: n=6. (F) HDL from the 
complete LOF carriers was significantly enriched in longer chain phospholipids, whereas no 
significant differences were observed in partial LOF carriers. Wt: n=4; PLOF: n=8; CLOF: n=6.   
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